Home >> Pharmaceuticals >> Food & Beverage >>

Errant Gene Therapeutics, LLC - Product Pipeline Review - 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 23 | Code: MRS - 18288

Errant Gene Therapeutics, LLC - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Errant Gene Therapeutics, LLC - Product Pipeline Review - 2015’, provides an overview of the Errant Gene Therapeutics, LLC’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Errant Gene Therapeutics, LLC’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Errant Gene Therapeutics, LLC including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Errant Gene Therapeutics, LLC’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Errant Gene Therapeutics, LLC’s pipeline products

Reasons to buy

- Evaluate Errant Gene Therapeutics, LLC’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Errant Gene Therapeutics, LLC in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Errant Gene Therapeutics, LLC’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Errant Gene Therapeutics, LLC and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Errant Gene Therapeutics, LLC
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Errant Gene Therapeutics, LLC and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Errant Gene Therapeutics, LLC Snapshot 4
Errant Gene Therapeutics, LLC Overview 4
Key Information 4
Key Facts 4
Errant Gene Therapeutics, LLC - Research and Development Overview 5
Key Therapeutic Areas 5
Errant Gene Therapeutics, LLC - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Errant Gene Therapeutics, LLC - Pipeline Products Glance 9
Errant Gene Therapeutics, LLC - Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
Errant Gene Therapeutics, LLC - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
Errant Gene Therapeutics, LLC - Drug Profiles 12
Thalagen 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
CG-1521 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Trichosic 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Gene Therapy for Sickle Cell Anemia 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Errant Gene Therapeutics, LLC - Pipeline Analysis 17
Errant Gene Therapeutics, LLC - Pipeline Products by Target 17
Errant Gene Therapeutics, LLC - Pipeline Products by Route of Administration 18
Errant Gene Therapeutics, LLC - Pipeline Products by Molecule Type 19
Errant Gene Therapeutics, LLC - Pipeline Products by Mechanism of Action 20
Errant Gene Therapeutics, LLC - Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 22
Contact Us 22
Disclaimer 23

List of Tables
Errant Gene Therapeutics, LLC, Key Information 4
Errant Gene Therapeutics, LLC, Key Facts 4
Errant Gene Therapeutics, LLC - Pipeline by Indication, 2015 6
Errant Gene Therapeutics, LLC - Pipeline by Stage of Development, 2015 7
Errant Gene Therapeutics, LLC - Monotherapy Products in Pipeline, 2015 8
Errant Gene Therapeutics, LLC - Phase I, 2015 9
Errant Gene Therapeutics, LLC - Preclinical, 2015 10
Errant Gene Therapeutics, LLC - Discovery, 2015 11
Errant Gene Therapeutics, LLC - Pipeline by Target, 2015 17
Errant Gene Therapeutics, LLC - Pipeline by Route of Administration, 2015 18
Errant Gene Therapeutics, LLC - Pipeline by Molecule Type, 2015 19
Errant Gene Therapeutics, LLC - Pipeline Products by Mechanism of Action, 2015 20
Errant Gene Therapeutics, LLC, Other Locations 21

List of Figures
Errant Gene Therapeutics, LLC - Pipeline by Top 10 Indication, 2015 6
Errant Gene Therapeutics, LLC - Pipeline by Stage of Development, 2015 7
Errant Gene Therapeutics, LLC - Monotherapy Products in Pipeline, 2015 8
Errant Gene Therapeutics, LLC - Pipeline by Top 10 Target, 2015 17
Errant Gene Therapeutics, LLC - Pipeline by Top 10 Molecule Type, 2015 19
Errant Gene Therapeutics, LLC - Pipeline Products by Top 10 Mechanism of Action, 2015 20

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing